RESUMEN
The glucose intolerance developed during pregnancy is called gestational diabetes mellitus (GDM). GDM has become a severe risk for the health of both mother and baby. Astragaloside IV (AS-IV) is the dominant active component in Astragalus membranaceus and has been reported to have anti-inflammation and immune-regulation function. We aimed to demonstrate the function of AS-IV in the therapy of GDM and the molecular mechanism in this process. C57BL/KsJ-Lepdb/+ female mice were used as the GDM model. The mRNA levels of relative genes in this research were detected by quantitative real-time PCR. The protein levels of relative genes were analyzed by Western blot. Serum lipid level was measured with an ILab Chemistry Analyzer 300 PLUS. Glucose, insulin, and lipid profile levels in the GDM mice model were decreased by AS-IV treatment. AS-IV downregulated the expression of inflammatory genes and upregulated the expressions of anti-oxidant genes in the GDM mice model. AS-IV treatment reduced cAMP accumulation in liver and reduced hepatic gluconeogenesis in GDM mice. This study demonstrated that AS-IV treatment has an effective therapeutic function of GDM in a mice model through the regulation of cAMP accumulation and hepatic gluconeogenesis.
Asunto(s)
Diabetes Gestacional/tratamiento farmacológico , Medicamentos Herbarios Chinos/farmacología , Gluconeogénesis/efectos de los fármacos , Hipoglucemiantes/farmacología , Saponinas/farmacología , Triterpenos/farmacología , Administración Oral , Animales , Glucemia/análisis , Glucemia/metabolismo , AMP Cíclico/análisis , AMP Cíclico/metabolismo , Diabetes Gestacional/sangre , Diabetes Gestacional/diagnóstico , Diabetes Gestacional/genética , Modelos Animales de Enfermedad , Medicamentos Herbarios Chinos/uso terapéutico , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Gluconeogénesis/genética , Prueba de Tolerancia a la Glucosa , Humanos , Hipoglucemiantes/uso terapéutico , Insulina/sangre , Insulina/metabolismo , Leptina/genética , Lípidos/sangre , Hígado/efectos de los fármacos , Hígado/metabolismo , Metformina/farmacología , Metformina/uso terapéutico , Ratones , Ratones Transgénicos , Embarazo , Saponinas/uso terapéutico , Triterpenos/uso terapéuticoRESUMEN
BACKGROUND: Our study aimed to examine the effects of daily consumption of vitamin D3-supplemented yogurt (VDY) drink on insulin resistance and lipid profiles in pregnant gestational diabetes mellitus (GDM) patients. METHODS: Participants aged 24-32 years in their second trimester were randomly assigned to consume either plain yogurt or VDY daily for 16 weeks. Metabolic and lipid profiles including levels of fasting plasma glucose (FPG), serum insulin, triacylglycerol (TAG), total cholesterol (TC) and low-density lipoprotein (LDL) were assessed at baseline (week 0) and end of trial (week 16). RESULTS: After 16 weeks of intervention, insulin-related variables including FPG and serum insulin levels were markedly lower in VDY group participants. Insulin resistance parameters, such as homeostasis model of assessment of insulin resistance and ß cell function, were also significantly reduced in VDY group participants. Moreover, levels of TAG, TC and LDL, as well as the TC to high-density lipoprotein ratio, had also significantly decreased in the VDY group. CONCLUSION: Daily consumption of VDY drink improves insulin resistance and lipid profiles in women with GDM.